Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2289 - CONVERCE: evaluation of cobimetinib and vemurafenib combination treatment in patients with brain metastases from BRAFV600 mutated melanoma


09 Oct 2016


Poster display


Thierry Lesimple


Annals of Oncology (2016) 27 (6): 379-400. 10.1093/annonc/mdw379


T. Lesimple1, B. Campillo-Gimenez2, M.T. Leccia3, A. Mahmoudi4, C. Lebbe5

Author affiliations

  • 1 Oncology Department, Centre Eugene - Marquis, 35000 - Rennes/FR
  • 2 Santé Publique Et Médecine Sociale, Centre Eugene - Marquis, Rennes/FR
  • 3 Dermato-vénérologie, Photobiologie Et Allergologie, CH Mutualiste de Grenoble, Grenoble/FR
  • 4 Unité Hématologie/oncodermatologie, Roche France, Boulogne-Billancourt/FR
  • 5 Dermatology, Hôpital St. Louis, 75010 - Paris/FR


Abstract 2289


Brain Metastases (BM) occur in 10 to 20% of patients (pts) at initial diagnosis of metastatic melanoma (MM) and develop in up to 73% of pts with MM.

BRAFV600 mutations are found in around 50% of cutaneous melanomas. Vemurafenib, a BRAF inhibitor, is a standard 1st-line treatment of BRAFV600 MM in Europe, and recent data suggest a benefit for patients with BM.

Resistance to a monotherapy with a BRAF inhibitor is frequent. Results of a phase III trial comparing vemurafenib + cobimetinib (MEK inhibitor) to vemurafenib in pts with BRAF mutated MM showed improved PFS and OS. Patients with symptomatic BM were excluded from this study.

The objective of CONVERCE, a phase II interventional study, is to determine whether the combination of vemurafenib + cobimetinib is effective in the treatment of BRAFV600 mutated melanoma with BM.

Trial design

Pts with histologically confirmed metastatic cutaneous melanoma, mucosal melanoma, or melanoma of unknown primary origin, and BM for which surgical resection is not a reasonable option, will be enrolled into 3 cohorts (n = 137): neurologically asymptomatic pts with previously locally untreated (Cohort A) or treated (Cohort B) BM, and neurologically symptomatic patients with previously locally treated or not BM (Cohort C). Pts will be treated with vemurafenib 960 mg PO, twice daily from D1 to D28, continuously, and cobimetinib 60 mg PO, once daily, from D1 to D21 (1 cycle = 28 days) until progression (intracranial or extracranial), unacceptable toxicity, withdrawal of consent, death or decision of the investigator. The primary endpoint is the complete or partial intracranial response rate in cohort A based on the evaluation of patient's best tumor response assessed by the centralized review committee according to modified RECIST 1.1 criteria). Secondary endpoints include objective intracranial response rates in cohorts B and C; intracranial duration of response, progression-free survival, overall response rate and overall survival in all cohorts; safety; pharmacokinetic study including cerebrospinal fluid, kinetic study of BRAF mutation rate in circulating tumor DNA; pharmacogenetics study. Preliminary results are expected in 2018.

Clinical trial identification

ClinicalTrials.gov Identifier: NCT02537600

Legal entity responsible for the study





T. Lesimple: Roche, BMS, Novartis, MSD. A. Mahmoudi: Roche. C. Lebbe: Roche, BMS, Novartis, MSD, Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings